title: Potent radioprotective effects of combined regimens of famotidine and vitamin C against radiation-induced micronuclei in mouse bone marrow erythrocytes.
abstract: To investigate the radioprotective effect of the combination of famotidine and vitamin C against radiation-induced micronucleus formation in mouse bone marrow erythrocytes, various doses of famotidine or vitamin C or combinations thereof were administered intraperitoneally to adult male NMRI mice 2 h before 2 and 4 Gy γ-irradiation. The frequency of micronucleated polychromatic erythrocytes (MnPCEs) was scored in 5,000 polychromatic erythrocytes (PCEs), and the cell proliferation ratio [PCE/(PCE + NCE); NCE = normochromatic erythrocytes] was also calculated for each treatment group. Data were statistically evaluated using one-way ANOVA test. The results show that pretreatment with various doses of famotidine and vitamin C before γ-irradiation significantly reduced the frequency of MnPCEs with a protection factor (PF) of 2 and 1.7, respectively. Pretreatment with vitamin C also significantly increased the cell proliferation ratio, while famotidine had no effect. Combination of famotidine and vitamin C was more effective in reducing MnPCEs than each compound alone, leading to a PF of 4.3 after irradiation. Cell proliferation ratio was also significantly improved by the combination compared with the irradiated control groups. Both famotidine and vitamin C are potent scavengers of free radicals and reactive oxygen species, especially OH(·). The combination of the two compounds probably further enhances this activity, thus leading to high bone marrow protection.
authors: Department of Radiology, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran, M.zangeneh@sbmu.ac.ir.
authors: M
authors: M
authors: Zangeneh
authors: H
authors: H
authors: Mozdarani
authors: A
authors: A
authors: Mahmoudzadeh
mesh_terms: D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000166:cytology*; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D004347:Drug Interactions; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000528:radiation effects*; D015738:Famotidine / Q000494:pharmacology*; D005720:Gamma Rays / Q000009:adverse effects; D008297:Male; D051379:Mice; D015162:Micronucleus Tests; D011837:Radiation-Protective Agents / Q000494:pharmacology*
chemical_list: D011837:Radiation-Protective Agents; D015738:Famotidine; D001205:Ascorbic Acid
references: Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):97-102
references: 11917293
references: Appl Radiat Isot. 2004 Nov;61(5):929-32
references: 15308170
references: Mutat Res. 1975 Feb;31(1):9-15
references: 48190
references: Int J Radiat Biol. 1993 Aug;64(2):189-94
references: 8103543
references: Mutat Res. 2001 Apr 5;491(1-2):1-7
references: 11287291
references: Anticancer Res. 1996 Jul-Aug;16(4A):1749-54
references: 8712695
references: J Clin Biochem Nutr. 2007 Mar;40(2):74-81
references: 18188408
references: Eur J Clin Invest. 1994 Jul;24(7):476-81
references: 7957505
references: Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1475-81
references: 16472936
references: J Radiat Res. 2010;51(2):145-56
references: 19959877
references: Res Commun Mol Pathol Pharmacol. 1996 Dec;94(3):271-87
references: 9029674
references: J Clin Oncol. 2007 Sep 10;25(26):4084-9
references: 17827457
references: Radiat Res. 2008 Apr;169(4):384-96
references: 18363433
references: Science. 1988 Jun 3;240(4857):1302-9
references: 3287616
references: Mutat Res. 2000 Nov 20;455(1-2):155-66
references: 11113474
references: Mutat Res. 2008 Jan 8;649(1-2):71-8
references: 17851119
references: Teratog Carcinog Mutagen. 2002;22(6):443-50
references: 12395405
references: Mutat Res. 1998 Sep 11;417(2-3):85-94
references: 9733928
references: Radiat Res. 2004 Dec;162(6):711-28
references: 15548121
references: Int J Radiat Biol. 2004 May;80(5):347-54
references: 15223767
references: Mutat Res. 1994 Jan-Feb;323(1-2):11-20
references: 7508561
references: Pharmacol Ther. 1988;39(1-3):213-4
references: 2849126
references: Mutat Res. 1983 Sep;123(1):61-118
references: 6888413
references: Reproduction. 2009 Jan;137(1):35-43
references: 18827066
references: J Biosci Bioeng. 2008 Jun;105(6):586-94
references: 18640597
references: Adv Exp Med Biol. 2008;614:165-78
references: 18290327
references: Int J Radiat Biol. 1990 Jan;57(1):97-101
references: 1967298
references: J Radiat Res. 2003 Jun;44(2):145-9
references: 13678344
references: J Radiat Res. 2001 Mar;42(1):21-37
references: 11393887
references: Pharmacol Ther. 1988;39(1-3):189-93
references: 3059367
references: Biochem Biophys Res Commun. 1990 Jun 15;169(2):430-6
references: 2162665
references: Health Phys. 2005 Nov;89(5):531-45
references: 16217197
references: Sheng Li Xue Bao. 1989 Dec;41(6):597-601
references: 2576333
references: J Radiat Res. 2007 Mar;48(2):129-34
references: 17299251
references: Drugs. 1992 Nov;44(5):709-19
references: 1280563
references: J Nucl Med. 1993 Apr;34(4):637-40
references: 8455081
references: Prostate. 2014 Jan;74(1):41-7
references: 24019126
references: Curr Drug Targets. 2010 Nov;11(11):1352-65
references: 20583981
references: Mutat Res. 1974 May;23(2):197-212
references: 4275776
references: Chem Biol Interact. 1993 Feb;86(2):119-27
references: 8095439
references: Eur J Biochem. 2003 Jul;270(14):3101-6
references: 12846844
references: Mutat Res. 1980 Mar;75(2):191-202
references: 7366601
references: J Am Assoc Lab Anim Sci. 2011 Sep;50(5):600-13
references: 22330705
references: Science. 1949 Aug 26;110(2852):213-4
references: 17811258
references: J Clin Oncol. 2000 Jun;18(11):2226-33
references: 10829042
references: Mutat Res. 1997 Sep 18;393(1-2):157-63
references: 9357573
references: Mutat Res. 1994 Jun;312(3):293-304
references: 7514741